

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 January 2022 (13.01.2022)



(10) International Publication Number
WO 2022/008719 A1

(51) International Patent Classification:

C07K 16/18 (2006.01) A61K 39/00 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/EP2021/069160

(22) International Filing Date:

09 July 2021 (09.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2010652.2 10 July 2020 (10.07.2020) GB

(71) Applicant: **WISTA LABORATORIES LTD.** [SG/SG];
25 Bukit Batok Crescent The Elitist #06-13, Singapore
658066 (SG).

(72) Inventor; and

(71) Applicant (for MG only): **HARRINGTON, Charles,
Robert** [GB/GB]; Institute of Medical Sciences, University
of Aberdeen, Aberdeen AB25 2ZD (GB).

(72) Inventors: **PALLIYIL SOMAN, Soumya**; Institute of
Medical Sciences, University of Aberdeen, Aberdeen AB25
2ZD (GB). **PORTER, Andrew, Justin, Radcliffe**; Insti-
tute of Medical Sciences, University of Aberdeen, Ab-
erdeen AB25 2ZD (GB). **WISCHIK, Claude, Michel**; Tau-
Rx Therapeutics Ltd., 395 King Street, Aberdeen AB24
5RP (GB). **ARASTOO, Mohammad**; Institute of Med-
ical Sciences, University of Aberdeen, Aberdeen AB25
2ZD (GB). **PENNY, Lewis, Kirk**; Institute of Med-
ical Sciences, University of Aberdeen, Aberdeen AB25
2ZD (GB). **LOFTHOUSE, Richard**; Institute of Medical
Sciences, University of Aberdeen, Aberdeen AB25 2ZD
(GB).

(74) Agent: **NEWTON, Michael Jonathan**; Lacon London 84
Theobalds Road, London WC1X 8NL (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2022/008719 A1

(54) Title: ANTI-TAU ANTIBODIES

(57) Abstract: The invention relates to specific binding molecules, such as antibodies, directed to key epitopes of tau. The specific binding molecules of the invention find applications in diagnostics and therapeutics of tauopathies including Alzheimer's disease.